<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">Ribavirin, a guanosine analog, has been used for the treatment of RNA viruses like hepatitis and respiratory syncytial virus. It interferes with the viral RNA synthesis and viral mRNA capping after undergoing metabolic activation to its active metabolite 
 <xref rid="b0550" ref-type="bibr">[110]</xref>. Past studies have highlighted the combination of ribavirin and interferon therapy as an effective treatment strategy for SARS-CoV and MERS-CoV 
 <xref rid="b0555" ref-type="bibr">[111]</xref>, 
 <xref rid="b0560" ref-type="bibr">[112]</xref>, 
 <xref rid="b0565" ref-type="bibr">[113]</xref>. Recently, Wang et al. highlighted the potential of ribavirin to inhibit SARS-CoV-2 
 <italic>in vitro</italic> in Vero E6 cells (EC
 <sub>50</sub> = 109.50 µM). Clinical trials are underway to evaluate the efficacy of ribavirin in the treatment of COVID-19 
 <xref rid="b0310" ref-type="bibr">[62]</xref>.
</p>
